Status In progress
Process STA Review
ID number 1379

Provisional Schedule

Expected publication 11 September 2019

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Gilead Sciences (idelalisib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Bloodwise
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologist


Associated public health groups Public Health England
  Public Health Wales NHS Trust
Comparator companies Accord Healthcare (bendamustine, fludarabine) not participating
  Actavis UK (fludarabine) not participating
  Aspen Pharma (chlorambucil) not participating
  Baxter Healthcare (cyclophosphamide) not participating
  Dr. Reddy's Laboratories (bendamustine) not participating
  medac GmbH (bendamustine) not participating
  Napp Pharmaceuticals (bendamustine) not participating
  Sandoz (cyclophosphamide, fludarabine) not participating
  Sanofi (fludarabine) not participating
  Zentiva (bendamustine) not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Reasearch
  National Cancer Research Institute


Key events during the development of the guidance:

Date Update
25 June 2019 Committee meeting: 2
01 November 2018 The next committee meeting for this appraisal will be rescheduled. This is to enable critique of additional evidence submitted by the company following ACD consultation.
04 October 2018 - 25 October 2018 Appraisal consultation
06 September 2018 Committee meeting: 1
05 April 2018 Invitation to participate
19 January 2018 Draft scope documents
16 January 2018 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance